Compare Amgen, Inc. (AMGN) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Marriott International Inc — how do they compare? Amgen, Inc. trades at $417.24 (market cap $224.14B), while Marriott International Inc trades at $355.13 (market cap $91.14B). The key difference: Amgen, Inc. is far larger — about 2.5× Marriott International Inc 's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | MAR | |
|---|---|---|
Market Cap | $224.14B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $402.54 |
52-Week Low | $271.18 | $259.04 |
Enterprise Value | $267.45B | $108.45B |
Dividend Yield | 2.43% | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Marriott International (MAR) trades at $355.34, up 1.98% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 9.62% net income margin and robust cash flow from operations of $3.21B in 2025, though its valuation remains elevated with a P/E of 36.18. Recent news highlights dividend declarations and AI-driven booking tools, while rising debt levels and Middle East weakness present challenges.
The outlook is mixed; analyst consensus leans bullish with a $387.31 price target, but high valuation and increasing debt-to-asset ratio (58.83% in 2025) cap upside potential. Key risks include regional volatility and competitive pressures, while fee revenue growth and a record pipeline offer opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
